CN101223166B - 噻唑基mglur5拮抗剂及其应用方法 - Google Patents

噻唑基mglur5拮抗剂及其应用方法 Download PDF

Info

Publication number
CN101223166B
CN101223166B CN2005800415189A CN200580041518A CN101223166B CN 101223166 B CN101223166 B CN 101223166B CN 2005800415189 A CN2005800415189 A CN 2005800415189A CN 200580041518 A CN200580041518 A CN 200580041518A CN 101223166 B CN101223166 B CN 101223166B
Authority
CN
China
Prior art keywords
ethynyl
thiazole
methyl isophthalic
compound
isophthalic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800415189A
Other languages
English (en)
Chinese (zh)
Other versions
CN101223166A (zh
Inventor
N·D·科斯福德
T·J·塞德斯
J·佩恩
J·R·罗普
D·黄
N·D·史密斯
S·F·潘
C·金
B·W·伊斯特曼
B·王
J·M·阿鲁达
J·-M·韦尼耶
X·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101223166A publication Critical patent/CN101223166A/zh
Application granted granted Critical
Publication of CN101223166B publication Critical patent/CN101223166B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
CN2005800415189A 2004-10-07 2005-10-06 噻唑基mglur5拮抗剂及其应用方法 Expired - Fee Related CN101223166B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61680504P 2004-10-07 2004-10-07
US60/616,805 2004-10-07
PCT/US2005/035921 WO2007050050A2 (en) 2004-10-07 2005-10-06 Thiazolyl mglur5 antagonists and methods for their use

Publications (2)

Publication Number Publication Date
CN101223166A CN101223166A (zh) 2008-07-16
CN101223166B true CN101223166B (zh) 2011-10-19

Family

ID=37968242

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800415189A Expired - Fee Related CN101223166B (zh) 2004-10-07 2005-10-06 噻唑基mglur5拮抗剂及其应用方法

Country Status (9)

Country Link
US (3) US7879882B2 (enExample)
EP (2) EP1893608B1 (enExample)
JP (2) JP5635727B2 (enExample)
CN (1) CN101223166B (enExample)
AT (1) ATE520692T1 (enExample)
AU (1) AU2005336513B2 (enExample)
CA (1) CA2583572C (enExample)
ES (1) ES2369783T3 (enExample)
WO (1) WO2007050050A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5635727B2 (ja) * 2004-10-07 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201124391A (en) * 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
EP2702050B1 (en) * 2011-04-26 2016-05-18 F.Hoffmann-La Roche Ag Pyrazolidin-3-one derivatives
MX337443B (es) * 2011-04-26 2016-03-07 Hoffmann La Roche Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
WO2014121883A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
CR20170536A (es) 2015-06-03 2018-02-01 Hoffmann La Roche Derivados de etinilo
SG10202002990XA (en) 2017-08-04 2020-05-28 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
US7462619B2 (en) * 1999-08-31 2008-12-09 Merck & Co., Inc. Pyridazine, pyrimidine and pyrazine ethyne compounds
US7365074B2 (en) * 1999-08-31 2008-04-29 Merck & Co., Inc. Pyridazine, pyrimidine and pyrazine ethyne compounds
CA2383524C (en) * 1999-08-31 2010-09-28 Merck & Co., Inc. Thiazolyl alkynyl compounds and methods of use thereof
US6956049B1 (en) * 1999-08-31 2005-10-18 Merck & Co., Inc. Methods of modulating processes mediated by excitatory amino acid receptors
US6903005B1 (en) * 2000-08-30 2005-06-07 Micron Technology, Inc. Method for the formation of RuSixOy-containing barrier layers for high-k dielectrics
US6551270B1 (en) 2000-08-30 2003-04-22 Snowden Pencer, Inc. Dual lumen access port
US20070060618A1 (en) * 2002-10-24 2007-03-15 Merck & Co., Inc. Alkyne derivatives as tracers for metabotropic glutamate receptor binding
JP5635727B2 (ja) * 2004-10-07 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Jeffrey R.Roppe,et al.5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3"-bipyridine:a highly potent,orally active metabotropic glutamate subtype 5(mGlu5) receptor antagonist with anxiolytic activity.Bioorganic & Medicinal Chemistry Letters.2004,14(15),3993-3996.
Jeffrey R.Roppe,et al.5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3"-bipyridine:a highly potent,orally active metabotropic glutamate subtype 5(mGlu5) receptor antagonist with anxiolytic activity.Bioorganic &amp *
Medicinal Chemistry Letters.2003,13(3),351-354. *
Medicinal Chemistry Letters.2004,14(15),3993-3996. *
Nicholas D.P.Cosford.[3H]-Methoxymethyl-MTEP and [3H]-Methoxy-PEPy：Potent and Selective Radioligands for the Metabotropic Glutamate Subtype 5(mGlu5) Receptor.Bioorganic & Medicinal Chemistry Letters.2003,13(3),351-354.
Nicholas D.P.Cosford.[3H]-Methoxymethyl-MTEP and [3H]-Methoxy-PEPy:Potent and Selective Radioligands for the Metabotropic Glutamate Subtype 5(mGlu5) Receptor.Bioorganic &amp *

Also Published As

Publication number Publication date
AU2005336513A1 (en) 2007-05-17
US8242143B2 (en) 2012-08-14
US20090203903A1 (en) 2009-08-13
JP2015013885A (ja) 2015-01-22
ES2369783T3 (es) 2011-12-05
JP5635727B2 (ja) 2014-12-03
US7879882B2 (en) 2011-02-01
EP1893608A2 (en) 2008-03-05
EP2380889A2 (en) 2011-10-26
EP1893608A4 (en) 2009-04-22
EP2380889A3 (en) 2012-01-18
WO2007050050A2 (en) 2007-05-03
ATE520692T1 (de) 2011-09-15
WO2007050050A3 (en) 2008-02-07
CA2583572A1 (en) 2006-04-07
EP1893608B1 (en) 2011-08-17
AU2005336513B2 (en) 2012-08-09
EP2380889B1 (en) 2013-06-26
US8609852B2 (en) 2013-12-17
CA2583572C (en) 2016-07-12
US20110230526A1 (en) 2011-09-22
JP2008516004A (ja) 2008-05-15
US20120289696A1 (en) 2012-11-15
CN101223166A (zh) 2008-07-16
AU2005336513A8 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
CN101223166B (zh) 噻唑基mglur5拮抗剂及其应用方法
CN100473647C (zh) 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
JP6931646B2 (ja) ベンゾラクタム化合物
TWI503316B (zh) 類大麻酚受體調節劑
CN102639530B (zh) 作为α7正向变构调节剂的吗啉代噻唑
CN103958497A (zh) 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN101605792A (zh) 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途
TW200908983A (en) Heterocyclic compounds and uses thereof
HUP0000914A2 (hu) 3-Aril-4 (3H)-kinazolinon-származékok atropizomerjei és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
KR20170061175A (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
CN104870441A (zh) 双环杂环化合物及其治疗用途
JP2003012653A (ja) キナゾリン誘導体
CN102762560A (zh) 二取代的杂芳基-稠合的吡啶
JP2018520201A (ja) Ｔｇｆベーター受容体アンタゴニスト
CN116438174A (zh) 化合物及其作为mif抑制剂的用途
WO2005056532A1 (en) Indazole derivatives which interact with the g-protein coupled receptor family
GB2572526A (en) Heterocyclic small molecule modulators of human STING
JP7293493B2 (ja) ７，８－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］アゼピン－６－オン化合物
US20230056497A1 (en) CD206 Modulators Their Use and Methods for Preparation
CN114436955A (zh) 四氢喹啉和苯并吗啉类衍生物或其盐及其制备方法和用途
CN101486683B (zh) 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
TW202434599A (zh) 造血前驅細胞激酶1之吡啶酮及嘧啶酮抑制劑
AU2012208981A1 (en) Thiazolyl mGluR5 antagonists and methods for their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121030

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: MSD CORP.

Free format text: FORMER NAME: SCHERING CORP (US)

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Patentee before: SCHERING Corp.

TR01 Transfer of patent right

Effective date of registration: 20121030

Address after: New jersey, USA

Patentee after: SCHERING Corp.

Address before: New jersey, USA

Patentee before: MERCK SHARP & DOHME Corp.

TR01 Transfer of patent right

Effective date of registration: 20220901

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Patentee before: MERCK SHARP & DOHME Corp.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111019

CF01 Termination of patent right due to non-payment of annual fee